PROCEPT BioRobotics Reports 19% Revenue Growth to $94.5 Million in Q2 2026

PROCEPT BioRobotics Corporation reported a revenue of $94.5 million for the second quarter of 2026, marking a 19% increase from $79.2 million in the same period of 2025. For the first half of 2026, the company generated $177.6 million in revenue, a 20% rise compared to $148.3 million in the first half of 2025. The growth in revenue was primarily driven by increased sales of robotic systems, handpieces, and service contracts, particularly in the U.S. market, which accounted for approximately 88% of total revenue. Despite the revenue increase, PROCEPT reported a net loss of $26.9 million for the second quarter, up from a loss of $19.6 million in the prior year, and a net loss of $58.5 million for the first half of 2026, compared to $44.3 million in the same period of 2025.

The company's operating expenses also rose significantly, with total operating expenses increasing by 21% to $89.8 million in the second quarter of 2026, compared to $73.9 million in the same quarter of 2025. Research and development expenses grew by 14% to $20.1 million, while selling, general, and administrative expenses surged by 24% to $69.7 million. The increase in expenses reflects the company's ongoing investments in commercialization and product development efforts. As of June 30, 2026, PROCEPT had cash and cash equivalents of $227.9 million, down from $286.5 million at the end of 2025, and an accumulated deficit of $700.1 million.

In terms of operational developments, PROCEPT's install base of AquaBeam and HYDROS robotic systems reached 1,036 units globally, with 816 units in the U.S. The company is focused on expanding its market presence by increasing the adoption of Aquablation therapy among urologists and enhancing system utilization within hospitals. The company has established strong relationships with key opinion leaders in the urology community, which has facilitated broader acceptance of its technology. Additionally, PROCEPT received FDA clearance for its next-generation HYDROS Robotic System in August 2024, further enhancing its product offerings.

Looking ahead, PROCEPT BioRobotics aims to continue its growth trajectory by expanding its sales force and increasing system utilization. The company is also focused on improving reimbursement and coverage decisions from third-party payors, which are critical for driving revenue growth. Management anticipates that existing cash reserves and projected revenue will be sufficient to meet capital requirements for at least the next twelve months. However, the company acknowledges that future funding may be necessary to support its growth initiatives, and it may seek additional financing through equity or debt securities if needed.